Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
6.72    0.00 (0.00%)
Bid:
5.50
Ask:
7.00
Spread: 1.50 (27.273%)
Market Cap: £425.55m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Notification under AIM Rule Schedule Two (g)

9 Oct 2013 08:48

RNS Number : 0827Q
Allergy Therapeutics PLC
09 October 2013
 



9 October 2013

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Notification under AIM Rule Schedule Two (g)

 

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, makes the following update announcement under AIM Rule Schedule Two (g) regarding Stephen Smith, a non-executive director of Allergy Therapeutics plc.

 

In addition to being a non-executive director of the Company, Stephen Smith acts as a 'company doctor' working with companies in distressed situations and in some cases the role has required a restructuring through a pre-planned administration/receivership or a planned insolvency to ensure an orderly winding down of the business. In providing these services, Stephen Smith was appointed as a director of the companies listed below in Table 1 which had administrators, receivers or liquidators appointed. These companies were part of the following groups:

 

· Texon International Group where Stephen Smith was appointed a director in 2004 and subsequently there was a restructuring in 2005 through a receivership which created a viable group where he continues to be a director.

 

· Ethel Austin Group where Stephen Smith was appointed a director in 2005. In 2008 lenders sold their secured loans to a company which appointed administrators a few days later.

 

· The Food & Drink Group where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 in a pre-planned process to achieve a sale of the profitable parts of the business.

 

· Paramount Restaurants Group where Stephen Smith was appointed a director in 2011 and later that year arranged a restructuring and subsequent pre-planned administration to achieve disposals of the profitable parts of the group.

 

· Ennstone plc where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 to complete a restructuring which ensured the viability of the UK and European businesses and protected the US business via a Chapter 11 process.

 

Table 1

 

Company

Comments

ACLM Limited (in administration)

Part of Ethel Austin Group

Bluelodge Limited (in administration)

Part of The Food & Drink Group

Burlington Restaurant Limited (in administration)

Part of The Food & Drink Group

Ennstone plc (in administration)

Holding company

Enterprises Realisations Limited (in administration)

Part of The Food & Drink Group

Ethel Austin Retail Group Limited (in administration)

Part of Ethel Austin Group

Ethel Austin Retail Holdings Limited (in administration)

Part of Ethel Austin Group

Futurestar Limited (in administration)

Part of The Food & Drink Group

Group Realisations Limited (in administration)

Part of The Food & Drink Group

Hartford Operations Limited (in administration)

Part of The Food & Drink Group

J Bar Limited (in administration)

Part of The Food & Drink Group

Montana plc (in administration)

Part of The Food & Drink Group

Newtaste Restaurants Limited (in administration)

Part of The Food & Drink Group

Noteframe Limited (in administration)

Part of Ethel Austin Group

Noxet Administration Services Limited

Part of Texon International group

PWC Realisations Limited (in administration)

Part of The Food & Drink Group

Texon Group Limited

Part of Texon International group

Texon Holdings Ltd (in liquidation)

Part of Texon International group

Texon International Limited

Part of Texon International group

The Food & Drink Group plc (in administration)

Part of The Food & Drink Group

USM (Holdings) Ltd

Part of Texon International group

Vantis Financial Management Limited (in administration)

Part of Vantis group

Vantis plc (in administration)

Part of Vantis group

Caffe Uno Brasseries Limited (in administration)

Part of Paramount Restaurants group

Charlotte Street Restaurants Limited

Part of Paramount Restaurants group

Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Craftbutton Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Leviathan Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Acquisitions Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Holdings Limited (in administration)

Part of Paramount Restaurants group

Paramount Limited (in administration)

Part of Paramount Restaurants group

Paramount Restaurants Limited (in administration)

Part of Paramount Restaurants group

Smile Restaurants Limited (in liquidation)

Part of Paramount Restaurants group

 

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 821

Ian Postlethwaite

Finance Director

Manuel Llobet

Chief Executive Officer

www.allergytherapeutics.com

Peel Hunt LLP

+44 (0) 20 7418 8900

James Steel / Dr. Vijay Barathan

FTI Consulting

+44 (0) 207 831 3113

Simon Conway / Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSDIRLAIIV
Date   Source Headline
10th Mar 20214:35 pmRNSPrice Monitoring Extension
10th Mar 20212:05 pmRNSSecond Price Monitoring Extn
10th Mar 20212:00 pmRNSPrice Monitoring Extension
8th Mar 20217:00 amRNSAGY to Present at H.C. Wainwright Conference
3rd Mar 20217:00 amRNSInterim Results for six months ended 31 Dec 2020
15th Jan 20217:00 amRNSBlock Listing Return and Total Voting Rights
13th Jan 20217:00 amRNSHalf Year Trading Update 2021 & Notice of Results
8th Jan 20214:41 pmRNSSecond Price Monitoring Extn
8th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSInitiation of peanut allergy biomarker study
14th Dec 20203:58 pmRNSDirector/PDMR Shareholding
8th Dec 20202:42 pmRNSResult of Annual General Meeting
20th Nov 20201:51 pmRNSGrant of Awards under Long Term Incentive Plan
20th Nov 20207:00 amRNSDirector/PDMR Shareholding
10th Nov 20207:05 amRNSAnnual Report & Accounts and AGM Notification
26th Oct 20207:00 amRNSInitiation of Grass MATA MPL exploratory study
12th Oct 20207:00 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSDirector Dealings and Issue of Equity
23rd Sep 20207:00 amRNSPreliminary Results
3rd Sep 20207:00 amRNSAGY secures VLP technology platform
20th Jul 20207:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15th Jul 202011:05 amRNSSecond Price Monitoring Extn
15th Jul 202011:00 amRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSTrading Update
9th Jul 20207:00 amRNSInvalidation of Birch MATA MPL phase III results
1st Jul 20205:15 pmRNSTotal Voting Rights
1st Jul 20205:14 pmRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:36 pmRNSPrice Monitoring Extension
24th Jun 20207:00 amRNSTrading Update
18th May 20202:05 pmRNSSecond Price Monitoring Extn
18th May 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:36 pmRNSPrice Monitoring Extension
22nd Apr 202010:11 amRNSEAACI review of adjuvants and formulations
1st Apr 20201:09 pmRNSGrant and Vesting of Awards
9th Mar 20207:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
4th Mar 20207:00 amRNSHalf-year Report
29th Jan 202012:00 pmRNSData for peanut allergy vaccine published in JACI
16th Jan 202012:25 pmRNSTrading Update & Notice of Results - Replacement
16th Jan 20208:00 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16th Jan 20207:00 amRNSHalf Year Trading Update & Notice of Results
2nd Dec 20199:57 amRNSHoldings in Company
29th Nov 201910:34 amRNSHoldings in Company
26th Nov 20197:00 amRNSUpdate to Grass MATA MPL Ph III clinical programme
25th Nov 201912:13 pmRNSResult of Annual General Meeting
22nd Oct 20199:23 amRNSAnnual Report and Accounts
26th Sep 20197:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25th Sep 20197:00 amRNSPreliminary Results
11th Jul 20197:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.